Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

V
Vélasco, Valérie

Institut Bergonié
(P 59) TARGETING ADORA2B TO HALT METASTASIS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: FROM MULTI-OMICS TO THERAPEUTIC INHIBITION
Valérie Vélasco
Favorite
(P 324) FULLY MATURE TERTIARY LYMHOID STRUCTURES AS PREDICTORS OF LOCAL RECURRENCE IN SOFT TISSUE SARCOMAS
Valérie Vélasco
Favorite
Völkl, Michael

Department of Medicine III, LMU University Hospital, Munich, Germany
(P 64) ATRX EXPRESSION CORRELATES WITH REDUCED IMMUNE CHECKPOINT EXPRESSION AND POOR SURVIVAL IN HIGH-RISK SOFT TISSUE SARCOMAS
Michael Völkl
Favorite
(P 437) CLINICAL DATA CONFIRM GALENIC PRINCIPLE AND DEMONSTRATE THERAPEUTIC POTENTIAL OF THE001 (DPPG2-TSL-DOX) PLUS REGIONAL HYPERTHERMIA IN SOFT TISSUE SARCOMA
Michael Völkl
Favorite
(P 443) FIRST-LINE PAZOPANIB IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS
Michael Völkl
Favorite
Vainer, Gilad W

Pathology Department, Sharett Institute for Oncology, Hadassah Medical Center & Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
(P 06) RAPID, POINT-OF-CARE DNA METHYLATION & MOLECULAR LANDSCAPE BASED SARCOMA CLASSIFICATION
Gilad W Vainer
Favorite
Valentin, Thibaud

OCR
(P 28) ADVANCING PRECISION ONCOLOGY IN SOFT TISSUE SARCOMAS: THE ROLE OF ITRAC IN METASTATIC RISK STRATIFICATION AND TREATMENT PERSONALIZATION
Thibaud Valentin
Favorite
Valentova, Iva

SOTIO Biotech a.s.
(P 257) TARGETING LEUCINE-RICH REPEAT-CONTAINING PROTEIN 15 (LRRC15): SOT106 ANTIBODY-DRUG CONJUGATE FOR SOFT TISSUE SARCOMA AND OSTEOSARCOMA TREATMENT
Iva Valentova
Favorite
Valenzuela, Raul

MD Anderson Cancer Center
(P 311) A FOLLOW-UP STUDY ON THE NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING FOR EXTREMITY DESMOID FIBROMATOSIS RESPONSE ASSESSMENT
Raul Valenzuela
Favorite
(P 317) BUILDING A PRE-SURGICAL MULTIPARAMETRIC-MRI-BASED PREDICTIVE TREATMENT RESPONSE MODEL FOR UNDIFFERENTIATED PLEOMORPHIC SARCOMA TO REPLACE RECIST
Raul Valenzuela
Favorite
(P 334) MRI VOLUMETRIC AND MODIFIED CHOI-BASED ASSESSMENT OF TREATMENT RESPONSE IN EXTREMITY DESMOID TUMORS TREATED WITH NIROGACESTAT OR SORAFENIB
Raul Valenzuela
Favorite
(P 351) THE ROLE OF SOCIOECONOMIC DISPARITIES ON SURVIVAL OUTCOMES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Raul Valenzuela
Favorite
(P 406) PILOT STUDY: CAN A MULTIPARAMETRIC MRI-DERIVED MODEL OUTPERFORM RECIST PREDICTING PATHOLOGY RESPONSE IN RHABDOMYOSARCOMA?
Raul Valenzuela
Favorite
(P 420) THE EFFECT OF CHEMOTHERAPY AND RADIOTHERAPY IN THE MULTIPARAMETRIC MRI-BASED ASSESSMENT OF TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Raul Valenzuela
Favorite
Valeri, Sergio

Fondazione Policlinico Universitario Campus Bio-Medico
(P 328) INNOVATING SARCOMA EDUCATION: EARLY OUTCOMES OF THE ITALIAN SOCIETY OF SURGICAL ONCOLOGY (SICO) SARCOMA SOCIAL MULTI-PLATFORM JOURNAL CLUB INITIATIVE
Sergio Valeri
Favorite
Valverde Morales, Claudia

Vall d’Hebron University Hospital
(P 71) GERMLINE POLYMORPHISMS IN THE VEGF PATHWAY AS PROGNOSTIC BIOMARKERS IN LOCALIZED HIGH-GRADE OSTEOSARCOMA: A STUDY BASED ON DATA FROM THE GEIS-33 PROTOCOL
Claudia Valverde Morales
Favorite
(P 389) UNRESECTABLE AND METASTATIC DEDIFFERENTIATED LIPOSARCOMA (DDLPS): INSIGHTS FROM A MULTICENTER REAL-WORLD COHORT (RWC)
Claudia Valverde Morales
Favorite
Valverde-Timana, Yanina

Institut Bergonié
(P 59) TARGETING ADORA2B TO HALT METASTASIS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: FROM MULTI-OMICS TO THERAPEUTIC INHIBITION
Yanina Valverde-Timana
Favorite
VAN ACKER, Nathalie

Institut Universitaire du Cancer de Toulouse
(P 12) DNA REPLICATION STRESS AND DEFICIENT HOMOLOGOUS RECOMBINATION IN OSTEOSARCOMA RISK AND THERAPY
Nathalie VAN ACKER
Favorite
van de Rijn, Matt

Stanford University
(P 37) DISSECTING THE TUMOR MICROENVIRONMENT OF UTERINE LEIOMYOSARCOMAS FOR TARGETED DRUG PREDICTIONS
Matt van de Rijn
Favorite
(P 68) MULTI-OMIC INTRA- AND INTER-TUMOR HETEROGENEITY OF BENIGN SMOOTH MUSCLE TUMORS
Matt van de Rijn
Favorite
(P 400) LONGITUDINAL EPIGENETIC AND TRANSCRIPTOMIC REMODELING ACROSS PRIMARY, IRRADIATED, AND LOCALLY RELAPSED SOFT TISSUE SARCOMAS
Matt van de Rijn
Favorite
(P 466) PATHOGENESIS AND THERAPEUTIC TARGETS IN KERATIN-POSITIVE GIANT CELL-RICH TUMOR
Matt van de Rijn
Favorite
van de Sande, Michiel

Leiden University Medical Center
(P 127) AN INTEGRATED CLINICAL GENOMIC AND TRANSCRIPTOMIC SUBGROUPING OF CENTRAL CHONDROSARCOMA
Michiel van de Sande
Favorite
(P 144) THE RISK OF PATHOLOGICAL FRACTURES AFTER INTRALESIONAL CURETTAGE IN ATYPICAL CARTILAGINOUS TUMOURS: A RETROSPECTIVE COHORT STUDY
Michiel van de Sande
Favorite
van den Akker, Brendy

Leiden University Medical Center
(P 127) AN INTEGRATED CLINICAL GENOMIC AND TRANSCRIPTOMIC SUBGROUPING OF CENTRAL CHONDROSARCOMA
Brendy van den Akker
Favorite
van der Graaf, Winette T.A.

Netherlands Cancer Institute
(P 315) ANALYSIS OF CHANGES IN T2-WEIGHTED SIGNAL INTENSITY AND TUMOR VOLUME AND EXPOSURE-RESPONSE IN THE RINGSIDE PHASE 2 STUDY OF VAREGACESTAT FOR DESMOID TUMORS
Winette T.A. van der Graaf
Favorite
(P 410) SUBGROUP ANALYSIS OF THE PHASE 2 PART OF THE RINGSIDE PHASE 2/3 TRIAL OF VAREGACESTAT FOR TREATMENT OF DESMOID TUMORS
Winette T.A. van der Graaf
Favorite
(P 442) TRIAL IN PROGRESS: A SINGLE-ARM, OPEN-LABEL PHASE 4 TRIAL OF NIROGACESTAT IN ADULT PREMENOPAUSAL FEMALES WITH DESMOID TUMORS
Winette T.A. van der Graaf
Favorite
(P 444) HEALTH-RELATED QUALITY OF LIFE (HRQOL) CHALLENGES IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA (EHE): ANALYSIS OF AN ULTRA-RARE SARCOMA GROUP
Winette T.A. van der Graaf
Favorite
van der Linde, Robert

Stanford University
(P 466) PATHOGENESIS AND THERAPEUTIC TARGETS IN KERATIN-POSITIVE GIANT CELL-RICH TUMOR
Robert van der Linde
Favorite
van der Wal, Robert

LUMC
(P 144) THE RISK OF PATHOLOGICAL FRACTURES AFTER INTRALESIONAL CURETTAGE IN ATYPICAL CARTILAGINOUS TUMOURS: A RETROSPECTIVE COHORT STUDY
Robert van der Wal
Favorite
van Dijk, Merel

Radboud University Medical Center
(P 197) DIFFERENTIAL EFFECTS OF ANAGRELIDE IN GASTROINTESTINAL STROMAL TUMORS (GIST) IN VITRO
Merel van Dijk
Favorite
Van Hare, Barbara

Rare Cancer Research Foundation
(P 350) THE PATTERN.ORG SARCOMA CONSORTIUM: BUILDING A MULTI-INSTITUTIONAL DATA RESOURCE FOR THE SARCOMA RESEARCH COMMUNITY
Barbara Van Hare
Favorite
van Houdt, W.J.

The Netherlands Cancer Institute
(P 456) OUTCOMES OF FIRST-LINE CHEMOTHERAPY IN ADVANCED ADULT-TYPE RHABDOMYOSARCOMAS: POOLED ANALYSIS OF CLINICAL TRIALS FROM THE EORTC SOFT TISSUE AND BONE SARCOMA GROUP
W.J. van Houdt
Favorite
van Ijzendoorn, David

Stanford University
(P 466) PATHOGENESIS AND THERAPEUTIC TARGETS IN KERATIN-POSITIVE GIANT CELL-RICH TUMOR
David van Ijzendoorn
Favorite
van Langevelde, Kirsen

LUMC
(P 144) THE RISK OF PATHOLOGICAL FRACTURES AFTER INTRALESIONAL CURETTAGE IN ATYPICAL CARTILAGINOUS TUMOURS: A RETROSPECTIVE COHORT STUDY
Kirsen van Langevelde
Favorite
van Praag, Veroniek

Leiden University Medical Center
(P 127) AN INTEGRATED CLINICAL GENOMIC AND TRANSCRIPTOMIC SUBGROUPING OF CENTRAL CHONDROSARCOMA
Veroniek van Praag
Favorite
van Riet, Bauke

Department of Radiotherapy, the Netherlands Cancer Institute
(P 41) THE IMPACT OF PAZOPANIB AND EXTREMITY RADIOTHERAPY ON TRANSAMINASES
Bauke van Riet
Favorite
van Tilburg, Cornelis

Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ)
(P 417) EFFICACY AND SAFETY OF LAROTRECTINIB (LARO) IN PATIENTS (PTS) WITH TRK FUSION SARCOMAS
Cornelis van Tilburg
Favorite
Van Tine, Brian

Washington University in St Louis School of Medicine
(P 315) ANALYSIS OF CHANGES IN T2-WEIGHTED SIGNAL INTENSITY AND TUMOR VOLUME AND EXPOSURE-RESPONSE IN THE RINGSIDE PHASE 2 STUDY OF VAREGACESTAT FOR DESMOID TUMORS
Brian Van Tine
Favorite
(P 410) SUBGROUP ANALYSIS OF THE PHASE 2 PART OF THE RINGSIDE PHASE 2/3 TRIAL OF VAREGACESTAT FOR TREATMENT OF DESMOID TUMORS
Brian Van Tine
Favorite
(P 413) EFFICACY OF NIROGACESTAT IN PATIENTS WITH DESMOID TUMORS AND PRESENCE OR ABSENCE OF POOR PROGNOSTIC FACTORS: POST HOC ANALYSES OF THE PHASE 3 DEFI TRIAL
Brian Van Tine
Favorite
(P 416) A PHASE 2 MULTICENTER OPEN-LABEL BASKET STUDY OF TAZEMETOSTAT IN ADULT PATIENTS WITH INI1-NEGATIVE EPITHELIOID SARCOMA – FINAL ANALYSIS
Brian Van Tine
Favorite
(P 439) AN OPEN LABEL MULTICENTER PHASE 2 STUDY WITH SAFETY LEAD IN OF INTRATUMORAL VUSOLIMOGENE ODERPAREPVEC IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANGIOSARCOMA
Brian Van Tine
Favorite
Vana, Pranaya

Tata Memorial Hospital
(P 387) TREATMENT PATTERNS AND PROGNOSTIC FACTORS IN LOCALISED SYNOVIAL SARCOMA: A RETROSPECTIVE STUDY FROM A TERTIARY CANCER CENTRE IN INDIA
Pranaya Vana
Favorite
Vance, Filipa

University of Bath
(P 207) LONG-TERM FOLLOW-UP AND LATE EFECTS MONITORING FOR UK BONE SARCOMA PATIENTS: A SERVICE MAPPING EXCERCISE
Filipa Vance
Favorite
Vanhersecke, Lucile

Institut Bergonié
(P 59) TARGETING ADORA2B TO HALT METASTASIS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: FROM MULTI-OMICS TO THERAPEUTIC INHIBITION
Lucile Vanhersecke
Favorite
(P 324) FULLY MATURE TERTIARY LYMHOID STRUCTURES AS PREDICTORS OF LOCAL RECURRENCE IN SOFT TISSUE SARCOMAS
Lucile VANHERSECKE
Favorite
Vanleeuw, Ulla

KU Leuven
(P 33) THE NOVEL TRANSCRIPTIONAL INHIBITORS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Ulla Vanleeuw
Favorite
(P 70) EPIDEMIOLOGY AND POTENTIAL CLINICAL RELEVANCE OF CONTACTIN-4 EXPRESSION IN SOFT TISSUE SARCOMA
Ulla Vanleeuw
Favorite
Vanzulli, Andrea

Fondazione IRCCS Istituto nazionale dei tumori
(P 308) IMPACT OF PSOAS MUSCLE RESECTION ON OUTCOMES IN PRIMARY RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Andrea Vanzulli
Favorite
(P 446) GDF-15 AS A PROGNOSTIC FACTOR IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA
Andrea Vanzulli
Favorite
(P 447) PAIN ASSESSMENT CRITERIA (PAC) ANTICIPATE RECIST PROGRESSION AND CORRELATE WITH BLOOD LEVELS OF GROWTH DIFFERENTIATION FACTOR 15 (GDF15) IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)
Andrea Vanzulli
Favorite
Vaseva, Angelina

Knight Cancer Institute at Oregon Health & Science University
(P 405) PAN-RAS INHIBITION AS A NOVEL THERAPEUTIC STRATEGY FOR RAS-DRIVEN RHABDOMYOSARCOMA
Angelina Vaseva
Favorite
Vasquez, Juan

Yale School of Medicine
(P 40) PRECLINICAL EFFICACY OF A PH-SENSITIVE EXATECAN PEPTIDE-DRUG-CONJUGATE IN RHABDOMYOSARCOMA
Juan Vasquez
Favorite
Vaz salgado, Maria Angeles

Hospital Universitario Ramón y Cajal
(P 71) GERMLINE POLYMORPHISMS IN THE VEGF PATHWAY AS PROGNOSTIC BIOMARKERS IN LOCALIZED HIGH-GRADE OSTEOSARCOMA: A STUDY BASED ON DATA FROM THE GEIS-33 PROTOCOL
Maria Angeles Vaz salgado
Favorite
Vaz, Fátima

Instituto Português de Oncologia de Lisboa Francisco Gentil
(P 372) CLINICOPATHOLOGICAL FEATURES AND OUTCOMES OF PATIENTS WITH KAPOSI SARCOMA: A SINGLE CENTER RETROSPECTIVE REAL WORLD ANALYSIS
Fátima Vaz
Favorite
Vaz, Maria Angeles

Hospital Universitario Ramón y Cajal
(P 389) UNRESECTABLE AND METASTATIC DEDIFFERENTIATED LIPOSARCOMA (DDLPS): INSIGHTS FROM A MULTICENTER REAL-WORLD COHORT (RWC)
Maria Angeles Vaz
Favorite
Veazey, Kylee

Ipsen
(P 464) EFFICACY OUTCOMES AMONG PATIENTS WITH ADVANCED EPITHELIOID SARCOMAS OF PROXIMAL-TYPE AND DISTAL-TYPE TREATED WITH TAZ: POST HOC ANALYSIS OF STUDY EZH-202
Kylee Veazey
Favorite
Veguilla, Fabiana

The University of Texas MD Anderson Cancer Center
(P 172) COMPARISON OF CELL SEGMENTATION METHODS IN SOFT TISSUE SARCOMA (STS) SPATIAL PROTEOMIC DATASETS
Fabiana Veguilla
Favorite
Velez Torres, Jaylou

University of Miami
(P 154) BCOR-MUTATED CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMA: A CLINICOPATHOLOGIC STUDY
Jaylou Velez Torres
Favorite
Venkataraman, Vinayak

Dana-Farber Cancer Institute
(P 235) AGNOSTIC INDICATION OF IMMUNE CHECKPOINT INHIBITORS (ICI): PATTERNS OF RESPONSE OF SARCOMAS
Vinayak Venkataraman
Favorite
Venkatramani, Raj

Texas Children's Cancer Center, Baylor College of Medicine
(P 250) OUTCOME OF INFANTS WITH RHABDOMYOSARCOMA: A REPORT FROM THE INTERNATIONAL SOFT TISSUE SARCOMA CONSORTIUM
Raj Venkatramani
Favorite
Vennam, Sujay

Stanford University
(P 68) MULTI-OMIC INTRA- AND INTER-TUMOR HETEROGENEITY OF BENIGN SMOOTH MUSCLE TUMORS
Sujay Vennam
Favorite
Venneker, Sanne

Leiden University Medical Center
(P 127) AN INTEGRATED CLINICAL GENOMIC AND TRANSCRIPTOMIC SUBGROUPING OF CENTRAL CHONDROSARCOMA
Sanne Venneker
Favorite
Vennik, Annabel

Massachusetts general hospital - Harvard medical school & Amsterdam University Medical Center Amsterdam
(P 294) RISK FACTORS FOR RECURRENCE AND COMPLICATIONS OF CT-GUIDED RADIOFREQUENCY ABLATION FOR THE TREATMENT OF OSTEOID OSTEOMA: A MULTI-INSTITUTIONAL ANALYSIS.
Annabel Vennik
Favorite
Verbeeck, Kimberly

KU Leuven
(P 33) THE NOVEL TRANSCRIPTIONAL INHIBITORS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Kimberly Verbeeck
Favorite
(P 70) EPIDEMIOLOGY AND POTENTIAL CLINICAL RELEVANCE OF CONTACTIN-4 EXPRESSION IN SOFT TISSUE SARCOMA
Kimberly Verbeeck
Favorite
Verbeke, Stéphanie

Institut Bergonié, INSERM U1312 BRIC
(P 42) PRECLINICAL VALIDATION OF M3554, A NOVEL ANTI-GD2 ANTIBODY-DRUG CONJUGATE, AND EPIGENETIC SENSITIZATION STRATEGIES IN SOFT TISSUE SARCOMAS
Stéphanie Verbeke
Favorite
(P 59) TARGETING ADORA2B TO HALT METASTASIS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: FROM MULTI-OMICS TO THERAPEUTIC INHIBITION
Stéphanie Verbeke
Favorite
Verheul, Henk

Erasmus MC Cancer Institute, Erasmus Medical Center
(P 194) UPDATED RESULTS FROM STRATEGIST 1: A PHASE 1/1B STUDY OF IDRX-42 (GSK6042981A) IN PATIENTS (PTS) WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST)
Henk Verheul
Favorite
Verhey, Ted

Arnie Charbonneau Cancer Institute and McCaig Institute for Bone and Joint Health
(P 238) INVESTIGATING HOW MACROPHAGES INFILTRATE THE TUMOUR MICROENVIRONMENT AND INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF STS
Ted Verhey
Favorite
(P 378) HIGH DOSE RADIATION THERAPY PROMOTES IMMUNE SUPPRESSIVE MACROPHAGE PHENOTYPES, WHEREAS LOW DOSE RADIATION THERAPY PROMOTES IMMUNOGENIC MACROPHAGE PHENOTYPES IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Ted Verhey
Favorite
Verret, Benjamin

Gustave roussy
(P 299) RECURRENCES AFTER PRIMARY RPS SURGERY IN A HIGH-VOLUME SARCOMA CENTER: A RETROSPECTIVE ANALYSIS ON 402 PATIENTS
Benjamin Verret
Favorite
Verspoor, Floortje

Amsterdam University Medical Center Amsterdam
(P 294) RISK FACTORS FOR RECURRENCE AND COMPLICATIONS OF CT-GUIDED RADIOFREQUENCY ABLATION FOR THE TREATMENT OF OSTEOID OSTEOMA: A MULTI-INSTITUTIONAL ANALYSIS.
Floortje Verspoor
Favorite
Verweij, Jaap

IDRx
(P 194) UPDATED RESULTS FROM STRATEGIST 1: A PHASE 1/1B STUDY OF IDRX-42 (GSK6042981A) IN PATIENTS (PTS) WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST)
Jaap Verweij
Favorite
Vianna, Karina

Centro Integrado de Oncologia de Curitiba
(P 128) ISOCITRATE DEHYDROGENASE 1 (IDH1) MUTATION TESTING IN THE PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA (CHONQUER)
Karina Vianna
Favorite
Viator, Melissa

MGH
(P 392) CLASSIFICATION AND DIFFERENTIATIONOF MYXOID LIPOSARCOMA AND MYXOMA WITH MACHINE LEARNING
Melissa Viator
Favorite
(P 392) DIFFERENTIATION OF MYXOMA AND MYXOID LIPOSARCOMA BASED ON RADIOMICS PHENOTYPES
Melissa Viator
Favorite
vibert, Julien

Gustave Roussy
(P 299) RECURRENCES AFTER PRIMARY RPS SURGERY IN A HIGH-VOLUME SARCOMA CENTER: A RETROSPECTIVE ANALYSIS ON 402 PATIENTS
Julien vibert
Favorite
Victor, Adrienne

University of Rochester
(P 04) EARLY ON-TREATMENT CIRCULATING TUMOR DNA DYNAMICS TO PREDICT RESPONSE IN PATIENTS WITH SARCOMA
Adrienne Victor
Favorite
Victor, Kristen

Memorial Sloan Kettering Cancer Center
(P 25) IDENTIFICATION AND VALIDATION OF NON-GENETICALLY ENCODED VULNERABILITIES IN EWING SARCOMA
Kristen Victor
Favorite
(P 48) PRECLINICAL ACTIVITY OF MEK INHIBITION IN COMBINATION WITH CHEMOTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Kristen Victor
Favorite
Vigorito, Raffaella

Fondazione IRCCS Istituto Nazionale Tumori
(P 331) MAINTENANCE THERAPY (M-TP) WITH DACARBAZINE (DTIC) AFTER FIRST-LINE ANTHRACYCLINE-BASED DOUBLET IN ADVANCED LEIOMYOSARCOMA (LMS) PATIENTS (PTS): OUTCOMES OF A CASE SERIES IN A SINGLE REFERRAL CENTER
Raffaella Vigorito
Favorite
Villavicencio-Valencia, Veronica

National Cancer Institute Mexico
(P 302) PREDICTORS AND OUTCOMES OF RECURRENT RETROPERITONEAL SARCOMA: A SINGLE-CENTER LATIN AMERICAN COHORT STUDY
Veronica Villavicencio-Valencia
Favorite
Vilson, Reshma

University of North Texas Health Science center Fort Worth
(P 460) OUTCOMES OF LATER-LINES SYSTEMIC THERAPIES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Reshma Vilson
Favorite
Vinader, Victoria

Bone Cancer Research Trust
(P 207) LONG-TERM FOLLOW-UP AND LATE EFECTS MONITORING FOR UK BONE SARCOMA PATIENTS: A SERVICE MAPPING EXCERCISE
Victoria Vinader
Favorite
Vincenzi, Bruno

Fondazione Policlinico Universitario Campus Bio-Medico
(P 61) HER2 TARGETING IN CHORDOMA: PRECLINICAL INSIGHTS ON TRASTUZUMAB DERUXTECAN
Bruno Vincenzi
Favorite
(P 70) EPIDEMIOLOGY AND POTENTIAL CLINICAL RELEVANCE OF CONTACTIN-4 EXPRESSION IN SOFT TISSUE SARCOMA
Bruno Vincenzi
Favorite
(P 231) INCREASED LIFETIME RISK (LTR) OF SOFT TISSUE SARCOMAS (STS) IN PATIENTS WITH LOW-RISK GASTROINTESTINAL STROMAL TUMORS (GIST): A RETROSPECTIVE ANALYSIS FROM THE ITALIAN SARCOMA GROUP (ISG)
Bruno Vincenzi
Favorite
(P 412) UNCOVERING HER2 OVEREXPRESSION IN SOFT TISSUE SARCOMAS (STS): INSIGHTS FROM THE CANCER GENOME ATLAS (TCGA)
Bruno Vincenzi
Favorite
Vincenzi, Bruno

Policlinico Universitario Campus Bio-Medico
(P 413) EFFICACY OF NIROGACESTAT IN PATIENTS WITH DESMOID TUMORS AND PRESENCE OR ABSENCE OF POOR PROGNOSTIC FACTORS: POST HOC ANALYSES OF THE PHASE 3 DEFI TRIAL
Bruno Vincenzi
Favorite
Vincenzi, Bruno

Fondazione Policlinico Universitario Campus Bio-Medico
(P 458) BETWEEN LYMPHOMAS AND SARCOMAS: A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG) ON HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN)
Bruno Vincenzi
Favorite
Visgauss, Julia

Duke University
(P 84) A MULTICENTER COMPARISON OF REVERSE TOTAL SHOULDER ARTHROPLASTY VERSUS HEMIARTHROPLASTY FOR ENDOPROSTHETIC RECONSTRUCTION FOLLOWING ONCOLOGIC RESECTION OF THE PROXIMAL HUMERUS
Julia Visgauss
Favorite
(P 125) TARGETING LCP1-MEDIATED METASTASIS IN CHONDROSARCOMA WITH OROXYLIN A
Julia Visgauss
Favorite
(P 126) SINGLE-CELL RNA SEQUENCING AND PROTEOMIC SPATIAL PROFILING REVEAL COMPLEX TUMOR MICROENVIRONMENT AND NOVEL IMMUNE INTERACTIONS IN CHONDROSARCOMA
Julia Visgauss
Favorite
(P 130) INVESTIGATING LCP1-MEDIATED ONCOGENIC SIGNALING IN CHONDROSARCOMA METASTASIS
Julia Visgauss
Favorite
(P 138) A MULTI-INSTITUTIONAL ARCHIVE AND DEEP LEARNING PIPELINE FOR QUANTIFYING CHONDROSARCOMA COMPOSITION
Julia Visgauss
Favorite
(P 177) DEEP LEARNING AND DIMENSIONALITY REDUCTION FOR SARCOMA SUBTYPING
Julia Visgauss
Favorite
(P 214) FINANCIAL TOXICITY IN PATIENTS WITH A HISTORY OF EXTREMITY AND PELVIC SARCOMA TREATMENT
Julia Visgauss
Favorite
Vitfell-Rasmussen, Joanna

Department of Oncology, Herlev University Hospital
(P 05) CONCORDANCE OF GENOMIC ALTERATIONS WITH CIRCULATING TUMOR DNA: INITIAL FINDINGS FROM A PILOT STUDY
Joanna Vitfell-Rasmussen
Favorite
(P 319) CARDIOTOXICITY AND OVERALL SURVIVAL IN PATIENTS WITH SARCOMA TREATED WITH DOXORUBICIN, OLARATUMAB AND DEXRAZOXANE: A REAL-WORLD EXPERIENCE IN DENMARK
Joanna Vitfell-Rasmussen
Favorite
Viza Gomes, Paula

Duke University School of Medicine
(P 138) A MULTI-INSTITUTIONAL ARCHIVE AND DEEP LEARNING PIPELINE FOR QUANTIFYING CHONDROSARCOMA COMPOSITION
Paula Viza Gomes
Favorite
(P 177) DEEP LEARNING AND DIMENSIONALITY REDUCTION FOR SARCOMA SUBTYPING
Paula Viza Gomes
Favorite
Vogl, Annette

Tubulis GmbH
(P 34) EXPRESSION OF ONCOFETAL ANTIGEN 5T4 IN SARCOMA SUBTYPES AND PRECLINICAL ACTIVITY OF TUB-030, A NOVEL 5T4-TARGETING ANTIBODY-DRUG CONJUGATE (ADC)
Annette Vogl
Favorite
Vokuhl, Christian

University Bonn
(P 250) OUTCOME OF INFANTS WITH RHABDOMYOSARCOMA: A REPORT FROM THE INTERNATIONAL SOFT TISSUE SARCOMA CONSORTIUM
Christian Vokuhl
Favorite
Volken, Larissa

Children's Cancer Institute
(P 266) TARGETING THE DNA DAMAGE RESPONSE TO ADVANCE PRECISION THERAPIES IN PAEDIATRIC SARCOMA
Larissa Volken
Favorite
von Bergwelt-Baildon, Michael

Department of Medicine III, LMU University Hospital, Munich, Germany
(P 64) ATRX EXPRESSION CORRELATES WITH REDUCED IMMUNE CHECKPOINT EXPRESSION AND POOR SURVIVAL IN HIGH-RISK SOFT TISSUE SARCOMAS
Michael von Bergwelt-Baildon
Favorite
(P 437) CLINICAL DATA CONFIRM GALENIC PRINCIPLE AND DEMONSTRATE THERAPEUTIC POTENTIAL OF THE001 (DPPG2-TSL-DOX) PLUS REGIONAL HYPERTHERMIA IN SOFT TISSUE SARCOMA
Michael von Bergwelt-Baildon
Favorite
(P 443) FIRST-LINE PAZOPANIB IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS
Michael von Bergwelt-Baildon
Favorite
von Kalle, Thekla

Institute of Radiology Olgahospital
(P 250) OUTCOME OF INFANTS WITH RHABDOMYOSARCOMA: A REPORT FROM THE INTERNATIONAL SOFT TISSUE SARCOMA CONSORTIUM
Thekla von Kalle
Favorite
von Mehren, Margaret

Division of Sarcoma Medical Oncology, Fox Chance Cancer Center
(P 194) UPDATED RESULTS FROM STRATEGIST 1: A PHASE 1/1B STUDY OF IDRX-42 (GSK6042981A) IN PATIENTS (PTS) WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST)
Margaret von Mehren
Favorite
(P 423) ZIFTOMENIB IN COMBINATION WITH IMATINIB IN ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) AFTER IMATINIB FAILURE: PHASE 1A/B STUDY OF SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY
Margaret von Mehren
Favorite
Vornicova, Olga

Division of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.
(P 395) ERIBULIN IN RECURRENT PRETREATED METASTATIC SOFT TISSUE SARCOMA. A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) REAL WORLD ANALYSIS
Olga Vornicova
Favorite
Voss, Rachel

Moffitt Cancer Center
(P 394) DUAL OR TRIMODALITY THERAPY VERSUS SURGERY ALONE IN RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST
Rachel Voss
Favorite
(P 453) OUTCOMES OF PLEOMORPHIC LIPOSARCOMA PATIENTS FOLLOWING MULTI-DISCIPLINARY MANAGEMENT WITHIN A TERTIARY CANCER CENTER
Rachel Voss
Favorite
Vyrva, Oleg

Ukrainian Academy of Medical Sciences
(P 151) SHOULD WE USE ADJUVANT CHEMOTHERAPY IN PATIENTS WITH LOCALIZED DEDIFFERENTIATED CHONDROSARCOMA (DDCS) OF THE PELVIS? AN ANALYSIS BY THE PELVIC DDCS STUDY GROUP
Oleg Vyrva
Favorite